These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23645220)

  • 1. Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens?
    Rajabally YA; Wong SL; Kearney DA
    J Neurol; 2013 Aug; 260(8):2052-6. PubMed ID: 23645220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy.
    Kuitwaard K; van Doorn PA; Vermeulen M; van den Berg LH; Brusse E; van der Kooi AJ; van der Pol WL; van Schaik IN; Notermans N; Tio-Gillen AP; van Rijs W; van Gelder T; Jacobs BC
    J Neurol Neurosurg Psychiatry; 2013 Aug; 84(8):859-61. PubMed ID: 23538070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
    Broyles R; Rodden L; Riley P; Berger M
    Postgrad Med; 2013 Mar; 125(2):65-72. PubMed ID: 23816772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP.
    van Doorn PA; Kuitwaard K; Jacobs BC
    J Peripher Nerv Syst; 2011 Jun; 16 Suppl 1():38-40. PubMed ID: 21696496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.
    Ritter C; Bobylev I; Lehmann HC
    J Neuroinflammation; 2015 Aug; 12():148. PubMed ID: 26268846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
    Rajabally YA; Afzal S
    J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy.
    Rajabally YA; Seow H; Wilson P
    J Peripher Nerv Syst; 2006 Dec; 11(4):325-9. PubMed ID: 17117941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intermittent intravenous immunoglobulin infusion prevented relapses in patients with remission-exacerbation type chronic inflammatory demyelinating polyradiculoneuropathy].
    Kanda F; Sekiguchi K; Oishi K; Hamaguchi H; Mitsui S; Kobessho H; Higuchi M; Shirafuji T; Ishihara H
    Rinsho Shinkeigaku; 2006 Mar; 46(3):236-8. PubMed ID: 16642939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in serum macrophage-related factors in patients with chronic inflammatory demyelinating polyneuropathy caused by intravenous immunoglobulin therapy.
    Ochi K; Kohriyama T; Higaki M; Ikeda J; Harada A; Nakamura S
    J Neurol Sci; 2003 Apr; 208(1-2):43-50. PubMed ID: 12639724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement.
    Kokubun N; Sada T; Yuki N; Okabe M; Hirata K
    Eur Neurol; 2013; 70(1-2):65-9. PubMed ID: 23796651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.
    Debs R; Reach P; Cret C; Demeret S; Saheb S; Maisonobe T; Viala K
    Int J Neurosci; 2017 Oct; 127(10):864-872. PubMed ID: 27918219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study).
    Kuitwaard K; Fokkink WR; Brusse E; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Merkies ISJ; Jacobs BC; van Doorn PA
    J Peripher Nerv Syst; 2018 Mar; 23(1):5-10. PubMed ID: 29119642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
    Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
    Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
    Mielke O; Bril V; Cornblath DR; Lawo JP; van Geloven N; Hartung HP; Lewis RA; Merkies ISJ; Sobue G; Durn B; Shebl A; van Schaik IN;
    J Peripher Nerv Syst; 2019 Mar; 24(1):72-79. PubMed ID: 30672067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Inflammatory Demyelinating Polyneuropathy: Time to Maximal Recovery in Patients Receiving Intravenous Immunoglobulin Therapy.
    Opala AR; Kennedy K; Baker SK
    Can J Neurol Sci; 2020 Jul; 47(4):531-537. PubMed ID: 32279669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
    Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA
    J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study.
    Adrichem ME; Bus SR; Wieske L; Mohammed H; Verhamme C; Hadden R; van Schaik IN; Eftimov F
    Eur J Neurol; 2020 Mar; 27(3):506-513. PubMed ID: 31571349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and availability of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy].
    Iijima M; Koike H; Sobue G
    Nihon Rinsho; 2012 Apr; 70(4):715-21. PubMed ID: 22568158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
    Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.